Literature DB >> 30857780

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.

David Wyles1, Ola Weiland2, Betty Yao3, Frank Weilert4, Jean-Francois Dufour5, Stuart C Gordon6, Albrecht Stoehr7, Ashley Brown8, Stefan Mauss9, Zhenzhen Zhang3, Tami Pilot-Matias3, Lino Rodrigues3, Federico J Mensa3, Fred Poordad10.   

Abstract

Entities:  

Keywords:  G/P; HCV; RAS; Resistance; Retreatment

Mesh：

Substances：

Year:  2019        PMID： 30857780     DOI： 10.1016/j.jhep.2019.01.031

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  19 in total

Review 1.  Management of Direct-Acting Antiviral Failures.

Authors:  Maryam Alimirah; Omar Sadiq; Stuart C Gordon
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-07-21

2.  Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.

Authors:  Oluwaseun Falade-Nwulia; Mark S Sulkowski
Journal:  J Infect Dis       Date:  2020-11-27       Impact factor: 5.226

3.  The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.

Authors:  Akito Nozaki; Masanori Atsukawa; Chisa Kondo; Hidenori Toyoda; Makoto Chuma; Makoto Nakamuta; Haruki Uojima; Koichi Takaguchi; Hiroki Ikeda; Tsunamasa Watanabe; Shintaro Ogawa; Norio Itokawa; Taeang Arai; Atsushi Hiraoka; Toru Asano; Shinichi Fujioka; Tadashi Ikegami; Toshihide Shima; Chikara Ogawa; Takehiro Akahane; Noritomo Shimada; Shinya Fukunishi; Hiroshi Abe; Akihito Tsubota; Takuya Genda; Hironao Okubo; Shigeru Mikami; Asahiro Morishita; Akio Moriya; Joji Tani; Yoshihiko Tachi; Naoki Hotta; Toru Ishikawa; Takeshi Okanoue; Yasuhito Tanaka; Takashi Kumada; Katsuhiko Iwakiri; Shin Maeda
Journal:  Hepatol Int       Date:  2020-03-03       Impact factor: 6.047

4.  Déjà vu All Over Again: Retreatment of HCV Direct Acting Antivirals Failures-Same Satisfactory Results, Same Unanswered Questions.

Authors:  Mark Sulkowski; David Wyles
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 20.999

5.  The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting.

Authors:  Gina Gamal Naguib; Tari George Michael; Yehia Elshazly; Maha Magdy Wahdan; Aya Mostafa; Ossama Ashraf Ahmed; Hany Dabbous; Heba Ismail Saad Aly; Mohamed Kamal Shaker; Hosam Samir Elbaz; Magdy El-Serafy; Wahid Doss; Sherief Abd-Elsalam; Manal Hamdy El-Sayed
Journal:  Virusdisease       Date:  2021-07-27

6.  Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report.

Authors:  Atsushi Naganuma; Ken Sato; Toru Fukuchi; Masashi Namikawa; Satoru Kakizaki; Toshio Uraoka; Hiroshi Ohnishi; Hiroaki Okamoto
Journal:  Clin J Gastroenterol       Date:  2019-08-02

Review 7.  Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications.

Authors:  Lisa Sandmann; Benjamin Schulte; Michael P Manns; Benjamin Maasoumy
Journal:  Visc Med       Date:  2019-05-21

Review 8.  Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.

Authors:  Ashley N Matthew; Florian Leidner; Gordon J Lockbaum; Mina Henes; Jacqueto Zephyr; Shurong Hou; Desaboini Nageswara Rao; Jennifer Timm; Linah N Rusere; Debra A Ragland; Janet L Paulsen; Kristina Prachanronarong; Djade I Soumana; Ellen A Nalivaika; Nese Kurt Yilmaz; Akbar Ali; Celia A Schiffer
Journal:  Chem Rev       Date:  2021-01-07       Impact factor: 60.622

Review 9.  A Review of Hepatitis B Virus and Hepatitis C Virus Immunopathogenesis.

Authors:  Corey Saraceni; John Birk
Journal:  J Clin Transl Hepatol       Date:  2021-05-31

Review 10.  Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?

Authors:  Virginia Solitano; Maria Corina Plaz Torres; Nicola Pugliese; Alessio Aghemo
Journal:  Viruses       Date:  2021-06-01       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.